Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study

Öz:

Objectives: Gallium-68 (Ga-68) prostate specific membrane antigen (PSMA) positron emission tomography (PET) has been shown to be moreaccurate than multiparametric prostate magnetic resonance imaging (MRI) in detection of primary prostate lesions. Using hybrid PET/MRI we aimto detect the correlation between SUVmax and apparent diffusion coefficient (ADC) in primary prostate lesions and to assess their prognostic valuein detection of lymph node (LN) metastasis.Methods: Twenty-six patients, who were diagnosed as having prostate cancer with biopsy and underwent Ga-68 PSMA PET/MRI together withbiparametric prostate MRI (bpMRI) were included. SUVmax, SUVmean and ADC were recorded for index lesions drawing a region of interest (ROI) of1 cm2 around the pixel with the highest SUVmax (ROI-1) and another ROI following borders of prostate tumor detected by bpMRI (ROI-2). Presenceof LN metastasis was recorded according to PSMA PET/MRI.Results: SUVmax was inversely correlated with ADC (ROI-1: p=0.010; ROI-2: p=0.017 for b=800). SUVmax and SUVmeans were both higher in patientswith LN metastasis and ADC was lower in patients with LN metastasis for ROI-1. SUVmax cut-off value of 19.8 for ROI-1 and 20.9 for ROI-2 hadsensitivity and specificity of 77.8% and 76.5%, respectively for detection of LN metastasis, whereas ADC (b=800) cut-off value of 0.92x10-3 mm2/shad sensitivity and specificity of 87.5% and 76.5%, respectively. SUVmax/ADC (b=800) ratio increased the sensitivity and specificity to 100% and82.4%, respectively.Conclusion: SUV and ADC values are inversely correlated in primary prostate lesions and the combined use of both values increases the diagnosticaccuracy of hybrid PET/MRI in the detection of primary prostate lesions.

Anahtar Kelime:

Ga-68 PSMA PET/MRG ile Tespit Edilen Primer Prostat Lezyonlarında SUVmaks ve Görünür Difüzyon Katsayısı Değerlerinin Korelasyonu ve Lenf Nodu Metastazlarında Önemi: Devam Eden Klinik Çalışmanın Ön Bulguları

Öz:

Amaç: Galyum-68 (Ga-68) prostat spesifik membran antijeni (PSMA) pozitron emisyon tomografinin (PET) primer prostat lezyonunu saptamada multiparametrik prostat manyetik rezonans görüntülemeden (MRG) daha doğru olduğu gösterilmiştir. Hibrit PET/MRG kullanarak primer prostat lezyonlarında SUVmaks ve görünür difüzyon katsayısı (ADC) arasındaki korelasyonu tespit etmeyi ve lenf nodu (LN) metastazı tespitinde prognostik değerlerini saptamayı amaçlıyoruz. Yöntem: Biyopsi ile prostat kanseri tanısı almış, biparametrik prostat MRG (bpMRG) ile birlikte Ga-68 PSMA PET/MRG yapılmış 26 hasta çalışmaya alındı. İndeks lezyonların SUVmaks, SUVortalama ve ADC değerleri, hem en yüksek SUVmaks olan piksel etrafında 1 cm2 çapında ilgi alanı (ROI) çizerek (ROI-1) hem de bpMRI tarafından tespit edilen prostat tümörünün sınırlarını takip eden bir başka ROI çizerek (ROI-2) kaydedildi. LN metastazı varlığı PSMA PET/MRG’ye göre belirlendi. Bulgular: SUVmaks ve ADC arasında ters korelasyon saptandı (b=800 için ROI-1: p=0,010; ROI-2: p=0,017). SUVmaks ve SUVortalama değerleri LN metastazlı hastalarda daha yüksek bulundu ve ADC değeri ROI-1 için LN metastazlı hastalarda daha düşüktü. SUVmaks sınır değeri ROI-1 için 19,8 ve ROI-2 için 20,9 alındığında LN metastazının saptanmasında duyarlılık ve özgüllük sırasıyla %77,8 ve %76,5 olarak bulundu. Buna karşılık ADC (b=800) sınır değeri 0,92x10-3 mm2/s alındığında duyarlılık ve özgüllük sırasıyla %87,5 ve %76,5 olarak saptandı. SUVmaks/ADC (b=800) oranı, duyarlılığı ve özgüllüğü sırasıyla %100 ve %82,4’e yükseltti. Sonuç: SUV ve ADC değerleri primer prostat lezyonlarında ters korelasyon gösterir ve her iki değerin birlikte kullanımı primer prostat lezyonlarının tespitinde hibrit PET/MRG’nin tanısal doğruluğunu arttırır.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Globan cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators. Prostate-Cancer Mortality at 11 Years of Follow-up. N Engl J Med 2012;366:981-990.
3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; ERSPC Investigators. Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-2035.
4. Tsodikov A, Gulati R, Etzioni R. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med 2018;168:608-609.
5. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A. Prevention and early detection of prostate cancer. Lancet Oncol 2014;15:484-492.
6. Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, Vickers A. Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. BJU Int 2012;109(Suppl 2):1-7.
7. Sonn GA, Natarajan S, Margolis DJ, MacAiran M, Lieu P, Huang J, Dorey FJ, Marks LS. Targeted Biopsy in the Detection of Prostate Cancer Using an Office Based Magnetic Resonance Ultrasound Fusion Device. J Urol 2013;189:86-91.
8. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenke P, Vickers AJ, Wake R, Shead DA, Freedman-Cass D. NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015. J Natl Compr Canc Netw 2015;13:1534- 1561.
9. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-137.
10. Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, Marks LS, Pinto P, Sonn GA, Taneja SS. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol 2016;196:1613-1618.
11. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SF, Perrotte F, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate 2014;74:210-216.
12. Barinka C, Rojas C, Slusher B, Pomper M. Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer. Curr Med Chem 2012;19:856-870.
13. Li Q, Xiang F, Lin X, Grajo JR, Yang L, Xu Y, Duan Y, Vyas U, Harisinghani M, Mahmood U, Samir AE. The Role of Imaging in Prostate Cancer Care Pathway: Novel Approaches to Urologic Management Challenges Along 10 Imaging Touch Points. Urology 2018;119:23-31.
14. Bravaccini S, Puccetti M, Bocchini M, Ravaioli S, Celli M, Scarpi E, De Giorgi U, Tumedei MM, Raulli G, Cardinale L, Paganelli G. PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis. Sci Rep 2018;8:4254.
15. Park SY, Kim CK, Park BK, Lee HM, Lee KS. Prediction of biochemical recurrence following radical prostatectomy in men with prostate cancer by diffusion-weighted magnetic resonance imaging: Initial results. Eur Radiol 2011;21:1111-1118.
16. Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T. Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Eur Urol 2016;70:829-836.
17. Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, Carroll PR, Hope TA. Diagnostic Accuracy of 68 Ga-PSMA-11 PET/ MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. Radiology 2018;289:730-737.
18. Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, Halac M, Talat Z, Araman A. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun 2015;36:582-587.
19. Greer MD, Choyke PL, Turkbey B. PI-RADSv2: How we do it. J Magn Reson Imaging 2017;46:11-23.
20. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators. MRITargeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 2018;378:1767-1777.
21. Wang X, Bao J, Ping X, Hu C, Hou J, Dong F, Guo L. The diagnostic value of PI‑RADS V1 and V2 using multiparametric MRI in transition zone prostate clinical cancer. Oncol Lett 2018;16:3201-3206.
22. Berger I, Annabattula C, Lewis J, Shetty DV, Kam J, Maclean F, Arianayagam M, Canagasingham B, Ferguson R, Khadra M, Ko R, Winter M, Loh H, Varol C. 68Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology. Prostate Cancer Prostatic Dis 2018;21:204-211.
23. Donato P, Roberts MJ, Morton A, Kyle S, Coughlin G, Esler R, Dunglison N, Gardiner RA, Yaxley J. Improved specificity with 68Ga PSMA PET/ CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. Eur J Nucl Med Mol Imaging 2019;46:20-30.
24. Al-Bayati M, Grueneisen J, Lütje S, Sawicki LM, Suntharalingam S, Tschirdewahn S, Forsting M, Rübben H, Herrmann K, Umutlu L, Wetter A. Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging. Urol Int 2018;100:164-171.
25. Jena A, Taneja R, Taneja S, Singh A, Kumar V, Agarwal A, Subramanian N. Improving diagnosis of primary prostate cancer with combined 68Gaprostate- specific membrane antigen-HBED-CC simultaneous PET and multiparametric MRI and clinical parameters. AJR Am J Roentgenol 2018;211:1246-1253.
26. Jyoti R, Jain TP, Haxhimolla H, Liddell H, Barrett SE. Correlation of apparent diffusion coefficient ratio on 3.0 T MRI with prostate cancer Gleason score. Eur J Radiol Open 2018;5:58-63.
27. Sokmen BK, Sokmen D, Ucar N, Ozkurt H, Simsek A. The correlation between biological activity and diffusion-weighted MR imaging and ADC value in cases with prostate cancer. Arch Ital Urol Androl 2017;89:277- 281.
28. Iraha Y, Murayama S, Kamiya A, Iraha S, Ogawa K. Diffusion-weighted MRI and PSA correlations in patients with prostate cancer treated with radiation and hormonal therapy. Anticancer Res 2012;32:4467-4471.
29. Ma T, Yang S, Jing H, Cong L, Cao Z, Liu Z, Huang Z. Apparent diffusion coefficients in prostate cancer: correlation with molecular markers Ki-67, HIF-1α and VEGF. NMR Biomed 2018:31.
30. Kim AY, Kim CK, Park SY, Park BK. Diffusion-Weighted Imaging to Evaluate for Changes From Androgen Deprivation Therapy in Prostate Cancer. Am J Roentgenol 2014;203:645-650.
31. Qi WX, Zhang Q, Li P, Zhang XM, Zhang GY, Wu B, Lu JJ, Jiang GL, Fu S. The predictive role of ADC values in prostate cancer patients treated with carbon-ion radiotherapy: initial clinical experience at Shanghai Proton and Heavy Ion Center (SPHIC). J Cancer Res Clin Oncol 2016;142:1361- 1367.
32. Ferraro DA, Rupp NJ, Donati OF, Messerli M, Eberli D, Burger IA. 68Ga- PSMA-11 PET/MR Can Be False Positive in Normal Prostatic Tissue. Clin Nucl Med 2019;44:291-293.
33. Pizzuto DA, Müller J, Mühlematter U, Rupp NJ, Töpfer A, Mortezavi A, Nagel H, Kranzbühler B, Eberli D, Burger IA. The central zone has increased 68Ga-PSMA-11 uptake: “Mickey Mouse ears” can be hot on 68Ga-PSMA-11 PET. Eur J Nucl Med Mol Imaging 2018;45:1335-1343.
34. Jena A, Taneja R, Taneja S, Singh A, Kumar V, Agarwal A, Subramanian N. Improving Diagnosis of Primary Prostate Cancer With Combined 68 Ga-Prostate-Specific Membrane Antigen–HBED-CC Simultaneous PET and Multiparametric MRI and Clinical Parameters. AJR Am J Roentgenol 2018;211:1246-1253.

APA	USLU BESLI R, Bakır B, Asa S, GUNER E, Demirdag C, Şahin O, Karayel E, SAGER S, Sayman H, Sonmezoglu K (2019). Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study. , 104 - 111. 10.4274/mirt.galenos.2019.63825
Chicago	USLU BESLI RABİA LEBRIZ,Bakır Barış,Asa Sertac,GUNER EKREM,Demirdag Cetin,Şahin Onur Erdem,Karayel Emre,SAGER Sait,Sayman Haluk Burçak,Sonmezoglu Kerim Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study. (2019): 104 - 111. 10.4274/mirt.galenos.2019.63825
MLA	USLU BESLI RABİA LEBRIZ,Bakır Barış,Asa Sertac,GUNER EKREM,Demirdag Cetin,Şahin Onur Erdem,Karayel Emre,SAGER Sait,Sayman Haluk Burçak,Sonmezoglu Kerim Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study. , 2019, ss.104 - 111. 10.4274/mirt.galenos.2019.63825
AMA	USLU BESLI R,Bakır B,Asa S,GUNER E,Demirdag C,Şahin O,Karayel E,SAGER S,Sayman H,Sonmezoglu K Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study. . 2019; 104 - 111. 10.4274/mirt.galenos.2019.63825
Vancouver	USLU BESLI R,Bakır B,Asa S,GUNER E,Demirdag C,Şahin O,Karayel E,SAGER S,Sayman H,Sonmezoglu K Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study. . 2019; 104 - 111. 10.4274/mirt.galenos.2019.63825
IEEE	USLU BESLI R,Bakır B,Asa S,GUNER E,Demirdag C,Şahin O,Karayel E,SAGER S,Sayman H,Sonmezoglu K "Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study." , ss.104 - 111, 2019. 10.4274/mirt.galenos.2019.63825
ISNAD	USLU BESLI, RABİA LEBRIZ vd. "Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study". (2019), 104-111. https://doi.org/10.4274/mirt.galenos.2019.63825

APA	USLU BESLI R, Bakır B, Asa S, GUNER E, Demirdag C, Şahin O, Karayel E, SAGER S, Sayman H, Sonmezoglu K (2019). Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study. Molecular Imaging and Radionuclide Therapy, 28(3), 104 - 111. 10.4274/mirt.galenos.2019.63825
Chicago	USLU BESLI RABİA LEBRIZ,Bakır Barış,Asa Sertac,GUNER EKREM,Demirdag Cetin,Şahin Onur Erdem,Karayel Emre,SAGER Sait,Sayman Haluk Burçak,Sonmezoglu Kerim Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study. Molecular Imaging and Radionuclide Therapy 28, no.3 (2019): 104 - 111. 10.4274/mirt.galenos.2019.63825
MLA	USLU BESLI RABİA LEBRIZ,Bakır Barış,Asa Sertac,GUNER EKREM,Demirdag Cetin,Şahin Onur Erdem,Karayel Emre,SAGER Sait,Sayman Haluk Burçak,Sonmezoglu Kerim Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study. Molecular Imaging and Radionuclide Therapy, vol.28, no.3, 2019, ss.104 - 111. 10.4274/mirt.galenos.2019.63825
AMA	USLU BESLI R,Bakır B,Asa S,GUNER E,Demirdag C,Şahin O,Karayel E,SAGER S,Sayman H,Sonmezoglu K Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study. Molecular Imaging and Radionuclide Therapy. 2019; 28(3): 104 - 111. 10.4274/mirt.galenos.2019.63825
Vancouver	USLU BESLI R,Bakır B,Asa S,GUNER E,Demirdag C,Şahin O,Karayel E,SAGER S,Sayman H,Sonmezoglu K Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study. Molecular Imaging and Radionuclide Therapy. 2019; 28(3): 104 - 111. 10.4274/mirt.galenos.2019.63825
IEEE	USLU BESLI R,Bakır B,Asa S,GUNER E,Demirdag C,Şahin O,Karayel E,SAGER S,Sayman H,Sonmezoglu K "Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study." Molecular Imaging and Radionuclide Therapy, 28, ss.104 - 111, 2019. 10.4274/mirt.galenos.2019.63825
ISNAD	USLU BESLI, RABİA LEBRIZ vd. "Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study". Molecular Imaging and Radionuclide Therapy 28/3 (2019), 104-111. https://doi.org/10.4274/mirt.galenos.2019.63825